Thomas Cable Increases Stake in Omeros Corporation
Insider Thomas Cable bought 15,000 shares of Omeros Corporation on June 18, 2026.
Key Points
- Thomas Cable purchased 15,000 shares of Omeros Corporation on June 18, 2026, as reported on Monday.
- Shares of Omeros Corporation traded near $10.28 with a market cap of $744 million and a P/E ratio of 9.02.
- Analysts from HC Wainwright & Co. and D. Boral Capital maintain buy ratings with targets up to $40.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Insider Thomas Cable made a notable move by purchasing 15,000 shares of Omeros Corporation (NasdaqGM: OMER) on June 18, 2026. This transaction, reported on Monday, did not involve a planned purchase and was executed at no specified price.
Insider Buying and Selling at Omeros Corporation
On June 18, 2026, several insiders, including Thomas Cable, each bought 15,000 shares of Omeros Corporation. These transactions were not part of a pre-arranged trading plan. Other insiders involved in similar transactions on the same day include Hood Leroy MD PhD, Perkinson Diana, Shah Rajiv, Bumol Thomas, Hanish Arnold, and Demopulos Peter MD.
Other Institutional Activity in Omeros Corporation
Among institutional investors, BlackRock, Inc. increased its holdings by 247,188 shares, bringing its total to 5,309,626 shares valued at approximately $56.1 million, marking a 4.9% increase. Ingalls & Snyder LLC added 110,724 shares, now holding 3,559,423 shares worth about $37.6 million, a 3.2% increase. Vanguard Capital Management LLC opened a new position with 2,983,259 shares valued at $31.5 million. UBS Group AG increased its stake by 117,749 shares to a total of 2,340,731 shares valued at $24.7 million, a 5.3% increase. State Street Corp also boosted its position by 346,049 shares, totaling 1,919,575 shares worth around $20.3 million, a 22.0% increase.
Omeros Corporation Stock Down 44.8%
Shares of Omeros Corporation traded near $10.28 on Monday. The company, with a market capitalization of approximately $744 million, has a P/E ratio of 9.02 and a beta of 2.526, indicating higher volatility compared to the market. The stock's 52-week range spans from a low of $2.95 to a high of $17.65. Its 50-day moving average stands at $12.22, while the 200-day moving average is $10.11. Omeros has a solid current ratio of 3.034 and a quick ratio of 2.479, indicating good short-term financial health.
$OMER stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On April 21, 2026, D. Boral Capital maintained its buy rating on Omeros Corporation, setting a price target of $36. HC Wainwright & Co. has also maintained a buy rating, with a target price of $40 as of January 8, 2026. The consensus recommendation for Omeros is a buy, with a mean price target of $40 based on one analyst opinion.
About Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company based in Seattle, Washington. It focuses on developing and commercializing small-molecule and protein therapeutics for immunologic diseases. The company's lead product candidate, Narsoplimab, is designed to treat conditions like stem-cell transplant-associated thrombotic microangiopathy and is in trials for COVID-19 and acute respiratory distress syndrome. Founded in 1994, Omeros is led by CEO Dr. Gregory A. Demopulos and employs around 175 people.
Bottom Line
Thomas Cable's recent purchase of Omeros Corporation shares adds to the insider interest in this biopharmaceutical company. With several institutional investors adjusting their positions, Omeros remains a stock to watch. Analysts continue to support a buy rating with price targets suggesting potential upside. As always, remember that insider and institutional transactions are backward-looking and may not reflect current holdings.
Get Omeros Corporation alerts
New 13F filings, insider trades, and analyst moves on $OMER, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.